Bone Marrow Transplant For Lymphoma

In lymphoma the word transplant nearly always means your own cells. Which matters, because the two operations share a name and almost nothing else.

An autologous transplant gives you back marrow cells collected from you weeks earlier, and it exists to let a very high dose of chemotherapy be survivable, and an allogeneic transplant puts a donated immune system into you, and it exists to hunt lymphoma the chemotherapy cannot reach. The first counts as the standard operation in lymphoma, carries a low risk of dying from the procedure, and was proven in 1995. The second happens rarely, carries a substantial risk, and gets held back for situations where nothing else holds.

Whose cells

Somebody says transplant and a family pictures a donor, a matching test and a stranger somewhere on a register. In lymphoma that picture is wrong, and the misunderstanding costs weeks of unnecessary fear.

An autologous transplant uses your own stem cells. They are collected from your blood over a few days, frozen, and returned after a dose of chemotherapy high enough that the marrow would otherwise never recover. There is no donor, no matching, no rejection and no graft versus host disease. The transplant is not the treatment. The chemotherapy is the treatment, and the cells are what make it survivable.

An allogeneic transplant uses cells from another person. It brings an immune system that recognizes lymphoma as foreign and attacks it, which is a mechanism chemotherapy does not have. It also brings an immune system that can attack the patient. That second effect is why allogeneic transplant in lymphoma is uncommon, and why the conversation about it sounds so different.

Nearly every lymphoma patient who hears the word transplant is being offered the first one. Almost nobody is told so. Ask which, in the first appointment. Then write the answer down.

Two operations, one word

Five differences separate them, and every one of them changes what the next year of your life looks like.

How an autologous transplant runs

The sequence runs in a fixed order, and seeing the whole of it before starting any of it helps.

1. Salvage chemotherapy first, given to shrink the lymphoma and to prove it still responds to drugs. Whether it responds is the single most important thing the whole plan depends on.
2. Mobilization. Injections push stem cells out of the marrow and into the bloodstream over several days, usually after a chemotherapy dose.
3. Collection. Blood runs through a machine that separates out the stem cells and returns everything else, over one to three sessions of a few hours each.
4. Freezing and counting. The laboratory checks that enough cells were collected, and a low count means repeating the mobilization rather than proceeding.
5. High dose chemotherapy, given over roughly six days as an inpatient, and this is the part that actually treats the lymphoma.
6. The cells go back through a drip, usually two days later. Counts fall for around a week, recover over the next one, and discharge follows a few days after that.

What the hospital stay actually looks like

Expect two to four weeks as an inpatient, most of it in a single room with restricted visiting, and mouth ulceration is the symptom people remember, and it is treated with strong painkillers because it deserves them. Nausea, diarrhea, fevers and transfusions all belong to the same window. Almost everybody gets a fever at some point during the low count period and almost everybody is given antibiotics for it, which is expected rather than alarming. Hair goes and grows back. The tiredness afterward lasts far longer than families expect, typically three to six months, and it is the single thing patients say nobody warned them of properly.

The trial that established it

Autologous transplant for lymphoma rests on a single trial from 1995. It has never needed repeating.

Two hundred and fifteen patients with aggressive non-Hodgkin lymphoma that had relapsed were given salvage chemotherapy. The 109 whose disease responded were then randomly assigned to more chemotherapy or to high dose treatment with autologous rescue. Five year event free survival came out at 46 percent for the transplant group against 12 percent for chemotherapy alone. Five year overall survival was 53 percent against 32. Three patients died of the transplant itself and none died of the chemotherapy.

Those numbers date from 1995 and they still hold, because the comparison was clean and the effect was enormous, because what has changed since is not the result but the position it occupies, because a treatment that did not exist in 1995 now competes with it for the same patients.

Who it is for in non-Hodgkin lymphoma

Autologous transplant does not treat lymphoma first. It comes in when the first treatment fails and the disease proves it can still be pushed back.

Hodgkin lymphoma

Hodgkin lymphoma responds to first line treatment better than any of the others, which means the patients who reach a transplant conversation are a selected minority.

What the randomized evidence shows

European investigators randomized patients aged 16 to 60 whose Hodgkin lymphoma had relapsed and still responded to chemotherapy, and one group received more conventional chemotherapy and the other received high dose treatment with autologous rescue. Freedom from treatment failure at three years came out at 55 percent for the transplant group against 34 percent, and the benefit held whether the first remission had been long or short. Overall survival did not differ significantly between the two arms, which is a detail worth understanding rather than skipping, because it means the transplant bought a longer period without the disease returning without proving, in that trial, that it made people live longer.

Why it is still standard

Survival in the comparison arm was rescued partly by transplanting patients who relapsed again, which blurs the overall survival comparison in a way statisticians recognize and families rarely hear about, and most groups accepted the freedom from treatment failure result and made autologous transplant standard for chemosensitive relapsed Hodgkin lymphoma, and it has stayed there ever since. Patients under 60 who relapse and respond to salvage treatment get offered one.

Consolidation after the transplant

Transplanting relapsed Hodgkin lymphoma does not finish the job in everybody, and the patients at highest risk of it coming back can now be given something afterward. The something has a price.

One trial randomized 329 patients at high risk of relapse to receive an antibody drug conjugate or a placebo after their autologous transplant, starting within weeks of it, and progression free survival by independent review improved with a hazard ratio of 0.57, and median progression free survival came out at 42.9 months against 24.1. That came at a cost. Peripheral sensory neuropathy affected 56 percent of the treated group against 16 percent on placebo, and neutropenia 35 percent against 12. Deaths at the time of analysis were almost identical in the two arms, so the trial did not demonstrate a survival benefit, and the drug is therefore offered to patients whose risk of relapse is high enough to be worth the nerve damage. That conversation should name the neuropathy explicitly, because it can persist, and because a patient who plays an instrument or works with their hands may weigh it differently from one who does not.

Engineered cells arrive

Something else appeared in aggressive B cell lymphoma and it competes directly with the autologous transplant for the same patients at the same moment.

What it is

The same machine that collects stem cells collects T cells from the patient, and in a laboratory they are given a gene for a receptor that recognizes a protein on the surface of the lymphoma. The modified cells are grown, frozen, shipped back and given through a drip after a short course of chemotherapy to make room for them. From that point the treatment is a living one, because the cells multiply inside the patient and keep working for weeks.

The trial that moved the line

Until 2022 the standard answer for large B cell lymphoma that relapsed early was salvage chemotherapy followed by an autologous transplant. One trial changed that answer. Then two more arrived.

Three hundred and fifty nine patients were randomly assigned to engineered cells or to the standard plan of salvage chemotherapy followed by transplant. Median event free survival came out at 8.3 months against 2.0, with a hazard ratio of 0.40. At a median follow up of about two years, 41 percent of the engineered cell group were still event free against 16 percent. Overall response was 83 percent against 50, and complete response 65 percent against 32.

Read the comparison arm carefully, and two months of event free survival sounds catastrophic and it reflects something specific, which is that a large share of patients assigned to the standard plan never reached the transplant at all, because their lymphoma progressed during salvage chemotherapy. The transplant went unreached more than it was beaten.

Two more trials, two answers

Three randomized trials of engineered cells against the standard second line plan reported within months of each other. They did not all agree.

The one that agreed

A second trial randomized 184 patients to a different engineered cell product or to the standard plan. Median event free survival came out at 10.1 months against 2.3, with a hazard ratio of 0.35, and severe cytokine release syndrome occurred in 1 percent and severe neurological events in 4, which is a milder toxicity profile than the first trial reported. Prolonged low blood counts were commoner after the cells, at 43 percent against 3.

The one that did not

A third trial randomized 322 patients to another engineered cell product or to standard care and found nothing. Median event free survival was 3.0 months in both arms, with a hazard ratio of 1.07. Response rates came out at 46.3 percent against 42.5. The trial reported nothing, it appeared in the same journal in the same month as the first one, and it deserves attention rather than quiet omission.

Why the results differed

Three explanations get offered and all three probably contributed. The products differ as molecules and in design, so a result for one does not transfer to another, so the waiting time differed, and in the negative trial the median gap between collecting cells and infusing them was 52 days, during which a quarter of patients progressed. And the trial arms were not perfectly balanced, with more high grade lymphoma and more adverse prognostic features in the engineered cell group.

Where the field settled

Most groups now offer engineered cells rather than a transplant to patients whose large B cell lymphoma relapses within a year of first treatment, and continue to offer the transplant to patients who relapse later and still respond to salvage chemotherapy, and that split is not a compromise. It follows from what the trials actually enrolled.

What second line looks like now

For a patient whose aggressive B cell lymphoma comes back, the decision tree in 2026 has more branches than it had five years ago. That is progress. It is also confusing.

Where the transplant still wins

Reading on engineered cells gives the impression that autologous transplant is finished in lymphoma. It has not finished, and the places where it remains first choice are specific.

Relapsed Hodgkin lymphoma is still transplanted, because the randomized evidence supports it and because no engineered cell product has replaced it there, and mantle cell lymphoma in younger patients is still consolidated with a transplant in many protocols. Several T cell lymphomas are still transplanted in first remission, because relapse rates after chemotherapy alone are high and the alternatives are thin. Late relapsing large B cell lymphoma that responds to salvage chemotherapy is still transplanted, and the trials that moved the field enrolled early relapses rather than these patients. Beyond the disease categories there is a practical reason too, which is that an autologous transplant runs in any competent transplant unit with a collection machine and a freezer, while engineered cells require a manufacturing chain, an approved product and a center licensed to give it. In much of the world that difference decides what is actually available, and a page written as though it did not would be describing a smaller world than the one patients actually live in.

Allogeneic transplant in lymphoma

The donor operation exists in lymphoma and stays uncommon. That ratio is correct and not an oversight.

What it offers and what it costs

Donated immune systems recognize lymphoma cells as foreign and attacks them continuously, which is a mechanism no drug reproduces and which can hold disease that has defeated everything else. That forms the offer. Against it stands an immune system that also recognizes the skin, the gut, the liver, the eyes and the lungs as foreign, producing graft versus host disease that in its chronic form can last years and shapes the whole of the rest of life. In lymphoma, where an autologous transplant and now engineered cells cover most of the ground, the allogeneic operation is held back for disease that has relapsed after those, for certain T cell and mantle cell lymphomas with few remaining options, and occasionally for younger patients with aggressive disease and a good donor where the alternative is a series of temporary controls.

The allogeneic numbers

Anybody considering the donor operation for lymphoma should see the figures before the brochure.

• Consider it after relapse following both an autologous transplant and engineered cells, where remaining options are few.
• Consider it in T cell lymphomas that relapse early, where the graft versus lymphoma effect is one of the few mechanisms with a track record.
• Consider it where the marrow itself is involved in a way that makes collecting clean autologous cells impossible.
• Do not consider it while the lymphoma is growing unchecked. Transplanting active, chemotherapy resistant disease produces poor results whatever the donor.
• Ask any unit proposing one how many they perform a year in lymphoma specifically, because the number is usually small and experience matters more when volumes are low.

Follicular and indolent lymphomas

Slow growing lymphomas raise the transplant question differently, because the disease sits quietly for decades without ever needing aggressive treatment.

When the question arises

Follicular lymphoma gets managed with periods of treatment separated by periods of watching, and patients frequently live a long time without any transplant conversation. Two situations change that. The first involves early progression after the initial treatment, which identifies a group with a much worse outlook and where a transplant is sometimes used to consolidate a second remission. The second involves transformation, where the indolent disease changes into an aggressive one, at which point it is treated as the aggressive disease and an autologous transplant or engineered cells enter the discussion on those terms. Outside those two situations, a proposal to transplant an indolent lymphoma deserves a careful second look, because the disease is compatible with many years of ordinary life and the operation carries real risk.

Mantle cell and T cell lymphomas

Two groups sit apart from the rest, because in both the transplant is used earlier and with a different purpose.

Why these are treated differently

Mantle cell lymphoma behaves as though it belonged to both categories, growing steadily like an indolent disease and returning reliably like an aggressive one, and many protocols therefore consolidate a first remission in younger patients with an autologous transplant instead of waiting for relapse, although newer targeted drugs have begun to challenge that in trials and the position is genuinely moving. Peripheral T cell lymphomas are uncommon, respond less reliably to first line chemotherapy than B cell lymphomas, and relapse frequently enough that several groups consolidate a first remission with an autologous transplant as a matter of routine. Neither of these positions rests on evidence as strong as the 1995 trial, and both should be presented as reasonable practice supported by imperfect data rather than as settled fact.

The word that decides everything

One word runs through every trial on this page and it decides who benefits. Chemosensitive.

Doctors call a lymphoma chemosensitive when it shrinks in response to salvage chemotherapy given before the transplant. Both landmark trials enrolled only chemosensitive patients, which means the results describe that group and nobody else. High dose chemotherapy is still chemotherapy. A lymphoma that ignored a normal dose will frequently ignore a large one, so putting a chemotherapy resistant patient through a transplant delivers the risk without the mechanism, and this is why the sequence never starts with the transplant. Salvage treatment comes first, a scan follows, and the transplant is confirmed only if the scan shows the disease moving in the right direction. A family that understands this in advance reads the interval scan correctly. A family that does not experiences it as an unexplained delay, and then hears the words not suitable for transplant as a withdrawal of care rather than as the answer to the question everybody was asking.

The three options side by side

Three treatments now compete in aggressive B cell lymphoma, and families are rarely shown them together.

Narrow screens scroll this table sideways. Swipe or drag to reach every column.

Availability belongs in that table as much as biology does. The best option that cannot be reached is no option at all.

Collecting the cells

Patients worry over the collection far more than they need to, and over the chemotherapy far less.

What actually happens

Injections of a growth factor are given under the skin for several days, in most protocols after a dose of chemotherapy, and they push stem cells out of the marrow into the blood, and the commonest side effect is a deep ache in the hips and lower back, which reflects a marrow working hard and responds to simple painkillers. Collection then runs through a machine connected to a large vein, often through a line in the neck or the groin, and takes three to five hours. Blood leaves, passes through a centrifuge that skims off the stem cell layer, and returns. People read, watch films and talk through it. Tingling around the mouth from the anticoagulant used in the circuit is common and is corrected during the session. Nearly everyone needs one to three sessions. Where too few cells are collected, a second mobilization attempt follows, sometimes with an additional drug, and that delay is frustrating rather than dangerous. Nothing is removed from the bone itself, and the old image of a needle into the hip under general anesthetic belongs to donor marrow collection and not to this.

The risks, stated plainly

Of the three operations on this page the autologous transplant carries the least danger, and it remains a dangerous thing to go through.

In the 1995 trial three of the transplanted patients died of the procedure and none of the chemotherapy patients did. Modern supportive care has lowered that rate considerably in fit patients, and it has not removed it. Serious infection during the low count period is the main cause. Beyond the early weeks, the risks that matter are a second cancer of the blood years later, reduced fertility, and in some regimens lung and heart effects that appear long after everybody has stopped thinking about the transplant.

Fertility deserves its own sentence, because the conversation has to happen before conditioning rather than after it and it is the step most frequently skipped when things are moving quickly, and sperm banking takes a day or two. Egg or embryo freezing takes longer and sometimes cannot be fitted in, which is a reason to raise it in the first week and not the last.

Recovery, week by week

Knowing the shape of the months afterward is the single thing patients say would have helped most.

1. Weeks one and two after the cells. Counts fall, mouth ulceration peaks, fevers are treated with antibiotics and transfusions are given. This is the hardest stretch and it is expected.
2. Weeks two to four. Counts recover, eating becomes possible again, and discharge follows once fevers have settled and the neutrophil count is holding.
3. Month two. Clinic visits weekly, then less often. Energy is poor, taste is strange and appetite is unreliable. Most people are not ready to work.
4. Months three to six. Steady improvement with bad days mixed in. Hair regrows, sometimes a different texture. Vaccinations are restarted on a written schedule because the transplant erased the immunity you had.
5. Months six to twelve. Most people return to work in some form. Fatigue that persists past a year deserves investigating rather than accepting, since thyroid function, iron stores and mood are all treatable causes.

Tell your employer the honest timetable at the start. Families that plan for six months cope better than families that plan for six weeks and then improvise.

The published figures

Below sit the figures quoted across this page, each with the group of patients it came from, so that anything a team tells you has something to sit beside.

On a phone this table slides left and right. Drag it across to see the third column.

What to ask before agreeing

Six questions separate a unit that is weighing your case from one that is following a habit, and each of them has a short right answer.

This table scrolls sideways on a narrow screen. Slide it to reach the second column.

Two answers should worry you. A unit that cannot say whether your lymphoma is chemosensitive is proposing a treatment whose entire evidence base was built in chemosensitive patients. And a unit that describes engineered cells as having replaced transplant, or as having nothing to offer, has simplified a field where three randomized trials reported different things within a few months of each other.

Write the answers down

You will repeat them to three different people, in two languages, over several months, and a page of notes taken in the first appointment is worth more than any brochure handed to you at the end of it.

Deciding this from another country

Lymphoma treatment runs on a timetable, and arranging it across a border adds steps to a timetable that has no spare weeks in it.

What travel adds and what it buys

Time costs first. Reports have to be translated, a visa obtained and flights booked, and a relapsed lymphoma held by salvage chemotherapy does not wait politely while that happens, and continuity is the second, because a patient transplanted in one country and followed in another depends on a handover that has to be written properly or it does not exist. Money comes third and it belongs in the open. What drives the cost of an autologous transplant is the number of collection sessions needed, the conditioning regimen chosen, how long the inpatient stay runs, whether complications need intensive care and how long a companion stays. Against those sits the reason people travel, which is reaching a unit that performs the operation often enough to be good at it, and one that will say plainly when engineered cells or a donor transplant would serve you better than the operation it happens to offer.

Ask that last question early. The answer tells you what kind of unit you are dealing with.

What we arrange

Roughly two months away from home for an autologous transplant, and four or more for an allogeneic one, which makes the practical scaffolding the thing that decides whether a family reaches the end of it.

Send your reports first, at no charge. The pathology, the staging scans, the treatment given so far, the date the first treatment finished and any response assessment after salvage chemotherapy. What comes back is a written opinion saying which operation your lymphoma calls for, whether engineered cells would serve you better, and where it says the plan you already have is the right one, it says that in those words, and seven languages are spoken on the team, English, Arabic, French, Russian, Serbian, Romanian and Spanish, with interpreting in others arranged on request. One coordinator handles you from the first message to discharge, and you get a name and a direct number instead of a switchboard. For an autologous transplant, plan on fourteen to twenty eight nights as an inpatient and roughly four to six weeks nearby afterward while the clinic checks counts twice a week. For an allogeneic transplant, plan on twenty to thirty five nights inpatient and around ninety more nights within reach. Fitness to fly home is judged on blood counts, on infection and, after a donor transplant, on whether graft versus host disease is active, so nobody signs off a date in advance. The room has a bed for whoever stays with you, airport transfers and a hotel are arranged from this end, meals are prepared halal, vegetarian or diabetic as required, and there is a prayer room in the building. An invitation letter for your visa is issued around ten days before travel with the document list attached. Once you are home the coordinator stays reachable on WhatsApp, your vaccination and follow up schedule leaves with you written in English so a doctor anywhere can act on it, and a written review is sent at three months and again at one year.

What we will not claim

Hospital pages on lymphoma promise things. Here follows what this one will not.

No survival figure will be quoted to you before somebody has read your pathology, your scans and your response to salvage treatment, because a number produced without those describes a different patient. Nobody here will present an autologous transplant as the answer for a relapse where the randomized evidence now favors engineered cells, and nobody will present engineered cells as having retired the transplant, because one of the three trials that tested that was negative. Our own results will not be given to you as a single percentage without naming the patients who produced it, and and the procedure will not be described as safe, because people still die of it, rarely after an autologous transplant in a fit patient and considerably less rarely after a donor transplant. If another unit has handed you a clean number with no range attached, ask which patients it came from and watch what happens next.

Questions we are asked, a lymphoma transplant FAQ

References

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin lymphoma. N Engl J Med. 1995;333(23):1540-1545.
2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin disease, a randomised trial. Lancet. 2002;359(9323):2065-2071.
3. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression, a randomised double blind placebo controlled phase 3 trial. Lancet. 2015;385(9980):1853-1862.
4. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second line therapy for large B cell lymphoma. N Engl J Med. 2022;386(7):640-654.
5. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second line treatment in patients with relapsed or refractory large B cell lymphoma. Lancet. 2022;399(10343):2294-2308.
6. Bishop MR, Dickinson M, Purtill D, et al. Second line tisagenlecleucel or standard care in aggressive B cell lymphoma. N Engl J Med. 2022;386(7):629-639.
7. Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma directed conditioning and allogeneic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma, an open label randomised phase 2 trial. Lancet Oncol. 2014;15(7):757-766.